These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2026562)

  • 1. L-669,262, a potent HMG-CoA reductase inhibitor.
    Joshua H; Schwartz MS; Wilson KE
    J Antibiot (Tokyo); 1991 Mar; 44(3):366-70. PubMed ID: 2026562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
    Alberts AW
    Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regioselectivity and stereoselectivity in the metabolism of HMG-CoA reductase inhibitors.
    Vyas KP; Kari PH; Pitzenberger SM
    Biochem Biophys Res Commun; 1990 Feb; 166(3):1155-62. PubMed ID: 2306236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
    Saheki A; Terasaki T; Tamai I; Tsuji A
    Pharm Res; 1994 Feb; 11(2):305-11. PubMed ID: 8165193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.
    Vickers S; Duncan CA; Vyas KP; Kari PH; Arison B; Prakash SR; Ramjit HG; Pitzenberger SM; Stokker G; Duggan DE
    Drug Metab Dispos; 1990; 18(4):476-83. PubMed ID: 1976071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin.
    Cheng H; Rogers JD; Sweany AE; Dobrinska MR; Stein EA; Tate AC; Amin RD; Quan H
    Pharm Res; 1992 Dec; 9(12):1629-33. PubMed ID: 1488408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
    Newman A; Clutterbuck RD; Powles RL; Catovsky D; Millar JL
    Leuk Lymphoma; 1997 Feb; 24(5-6):533-7. PubMed ID: 9086443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.
    Nagata Y; Hidaka Y; Ishida F; Kamei T
    Biochem Pharmacol; 1990 Aug; 40(4):843-50. PubMed ID: 2167097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
    Serajuddin AT; Ranadive SA; Mahoney EM
    J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
    Slater EE; MacDonald JS
    Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
    Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase induce reductase accumulation and altered lamellar bodies in rat forestomach keratinocytes.
    Singer II; Kawka DW; Scott S; Bailey P; Kloss MW; Majka J; MacDonald JS
    Arterioscler Thromb; 1991; 11(5):1156-65. PubMed ID: 1911702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 9. The synthesis and biological evaluation of novel simvastatin analogs.
    Hartman GD; Halczenko W; Duggan ME; Imagire JS; Smith RL; Pitzenberger SM; Fitzpatrick SL; Alberts AW; Bostedor R; Chao YS
    J Med Chem; 1992 Oct; 35(21):3813-21. PubMed ID: 1433193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromatographic purification of some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Grahek R; Milivojevic D; Bastarda A; Kracun M
    J Chromatogr A; 2001 May; 918(2):319-24. PubMed ID: 11407578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
    Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans.
    Cheng H; Sutton SC; Pipkin JD; Zentner GM; Rogers JD; Schwartz JI; Mitchel YB; Grasing K; Schwartz MS; Amin RD
    Pharm Res; 1993 Nov; 10(11):1683-7. PubMed ID: 8290485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
    Krasovec M; Elsner P; Burg G
    Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.